Its subsidiary’s Phase III clinical trial of “Vitamettrazil” has completed the enrollment of the first patient.
April 16, 2026
Source: drugdu
33
On April 15, China Biopharmaceutical (01177) issued an announcement stating that its wholly-owned subsidiary, Lixin Pharmaceutical Technology (Shanghai) Co., Ltd., has independently developed a Class 1 innovative drug.Vitacoltobayumab (development code: LM-302) is undergoing a Phase III registration clinical trial in combination with a PD-1 monoclonal antibody as first-line treatment for CLDN18.2-positive locally advanced or metastatic gastric and gastroesophageal junction adenocarcinoma, and the first patient has been successfully enrolled.
LM-302 has been included in the Breakthrough Therapy Program by the China National Medical Products Administration for multiple indications and has received orphan drug designation from the U.S. Food and Drug Administration.
https://finance.eastmoney.com/a/202604153705999476.html
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- Maiweijian® (Denosumab Injection) New Indication Supplemental Application Accepted by NMPA April 16, 2026
- The first subject has been enrolled in the Phase II clinical trial in China for its innovative drug LY03017, which is used to treat Alzheimer’s disease and psychotic disorders. April 16, 2026
- The first subject has been enrolled in the Phase II clinical trial in China for its innovative drug LY03017, which is used to treat Alzheimer’s disease and psychotic disorders. April 16, 2026
- A multi-billion dollar market is fiercely competitive, with Huadong Medicine applying for marketing approval of its megglutinin weight loss product. April 16, 2026
- Another domestically developed AD drug successfully completed Phase III trials. April 16, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
